Biocartis granted rights to Thermo Fisher Scientific to distribute its rapid and fully automated molecular diagnostics Idylla platform in the US, including its accompanying assays, with a first focus on oncology products.
Rudi Pauwels, CEO of Biocartis, commented: "We are extremely proud to announce this collaboration. Thermo Fisher Scientific is a great match for Biocartis, holding an impressive track-record in improving patient diagnostics and increasing laboratory productivity. I am confident that this partnership will not only strengthen our commercialization efforts in the U.S., but also support us in taking the next step in our ambition of having an impact on molecular diagnostic testing throughout the world."
Mark Zacur, Vice President and General Manager of Thermo Fisher's healthcare market channel, added: "The Biocartis molecular diagnostics platform and assays are an important step forward in the fight against cancer. We are pleased to have been chosen as their channel for making these tests available to our customers in 2017."
Biocartis' proprietary Idylla platform, first launched in September 2014, enables Thermo Fisher Scientific to offer its U.S. customers access to a fully automated, real-time PCR-based molecular diagnostics system, which provides fast and easy access to molecular biomarker information. The Idylla platform encompasses the entire process from sample to result in a time frame of approximately two hours. With less than two minutes of hands-on time, Idylla is applicable for a wide range of clinical sample types, and it can analyze both RNA and DNA directly from an FFPE (formalin-fixed paraffin embedded) sample. The fully integrated system will enable U.S. laboratories to perform a broad range of molecular tests. Both parties expect to start commercial roll-out as of mid-2017. Biocartis will retain the right to sell both its Idylla(TM) platform and assays via direct sales channels.
More on Biocartis here